We think there are plenty of targets to get excited about in the field of immunokinase modulation, many with strong preclinical rationale and compelling human genetic linkages despite lacking clinical-stage pharmacologic validation.
FORBES: Immunokinase Drug Candidates: $12B in Value Creation and Counting